| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | 1,25,057.00 | 62.45 | 13.20 | 20.48% | 0.32 | 17.27% | 692.92 | 0.23% | 0.70 | 103.81 |
| Max Healthcare | 1,09,728.00 | 76.08 | 10.21 | 13.42% | 0.09 | 12.97% | 91.86 | 0.18% | 0.28 | 7.37 |
| Fortis Healthcare | 73,604.60 | 69.15 | 7.44 | 10.53% | 0.23 | 12.56% | 122.24 | 0.10% | 0.16 | 3.05 |
| Aster DM Healthcare | 40,962.60 | 95.95 | 9.69 | 8.48% | 0.31 | 10.10% | 83.23 | 0.38% | 0.46 | 5.20 |
| Narayana Hrudayalaya | 40,570.70 | 50.34 | 8.94 | 17.76% | 0.76 | 11.42% | 127.10 | 0.23% | 0.85 | 24.77 |
| Global Health | 36,176.70 | 65.28 | 9.13 | 14.05% | 0.06 | 15.26% | 149.24 | 0.04% | 0.77 | 18.46 |
| KRISHNA INST OF MED SCI L | 35,097.80 | 145.08 | 9.37 | 10.74% | 0.63 | 7.99% | 93.54 | 0.00% | 0.46 | 6.52 |
| Dr. Lal Path Labs | 27,697.10 | 54.33 | 11.04 | 20.13% | 0.07 | 25.56% | 8.90 | 1.56% | 1.01 | 30.45 |
| Syngene International | 17,755.40 | 56.03 | 3.67 | 7.76% | 0.04 | 9.67% | 116.55 | 0.28% | 0.67 | 7.58 |
| Poly Medicure | 17,614.20 | 54.92 | 5.67 | 10.37% | 0.08 | 12.71% | 301.18 | 0.20% | 0.53 | 33.15 |
| Particulars | Mar 2018 |
|---|---|
| Revenue | ₹4.33 |
| Other Income | ₹0.01 |
| Total Revenue | ₹4.34 |
| Total Expenses | ₹4.28 |
| Profit Before Tax | ₹0.06 |
| Tax | ₹0.10 |
| Profit After Tax | -₹0.03 |
| EPS - Basic | -₹0.03 |
| EPS - Diluted | -₹0.03 |
| Particulars | Mar 2018 |
|---|---|
| Profit before tax | -₹0.20 |
| Income before WC changes | -₹0.20 |
| Change in Assets | ₹1.84 |
| Change in Liabilities | ₹0.04 |
| Change in WC | ₹1.88 |
| Cash flow from Operations | ₹1.68 |
| Cash flow from Investing | -₹4.66 |
| Cash flow from Financing | ₹3.00 |
| Total Cash Flow | ₹0.02 |
| Cash (Start of the year) | ₹0.01 |
| Cash (End of the year) | ₹0.03 |
| Particulars | Mar 2018 |
|---|---|
| Non-Current Assets | ₹5.01 |
| Current Assets | ₹7.29 |
| Total Assets | ₹12.29 |
| Current Liabilities | ₹2.25 |
| Net Current Asset | ₹5.03 |
| Non-Current Liabilities | ₹0.44 |
| Equity Capital | ₹9.61 |
| Total Equity & Liabilities | ₹12.29 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Other Income | ₹3.67 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total Revenue | ₹3.67 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total Expenses | ₹0.16 | ₹3.80 | ₹0.14 | ₹0.12 |
| Profit Before Tax | ₹3.50 | -₹3.80 | -₹0.14 | -₹0.12 |
| Tax | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹3.50 | -₹3.80 | -₹0.14 | -₹0.12 |
| EPS - Basic | ₹2.70 | -₹2.92 | -₹0.11 | -₹0.09 |
| EPS - Diluted | ₹2.70 | -₹2.92 | -₹0.11 | -₹0.09 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹3.50 | -₹3.80 | -₹0.14 | -₹0.12 |
| Income before WC changes | ₹3.50 | -₹3.80 | -₹0.14 | -₹0.12 |
| Change in Assets | -₹3.63 | ₹3.76 | ₹0.03 | -₹0.01 |
| Change in Liabilities | ₹0.12 | ₹0.04 | ₹0.01 | ₹0.01 |
| Change in WC | -₹3.51 | ₹3.80 | ₹0.05 | ₹0.00 |
| Cash flow from Operations | ₹0.00 | ₹0.00 | -₹0.09 | -₹0.12 |
| Cash flow from Investing | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Cash flow from Financing | ₹0.00 | ₹0.00 | ₹0.09 | ₹0.12 |
| Total Cash Flow | ₹0.00 | ₹0.00 | -₹0.01 | ₹0.01 |
| Cash (Start of the year) | ₹0.01 | ₹0.01 | ₹0.01 | ₹0.01 |
| Cash (End of the year) | ₹0.01 | ₹0.01 | ₹0.01 | ₹0.01 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Current Assets | ₹8.84 | ₹5.21 | ₹8.97 | ₹9.09 |
| Total Assets | ₹8.84 | ₹5.21 | ₹8.97 | ₹9.09 |
| Current Liabilities | ₹0.30 | ₹0.18 | ₹0.14 | ₹0.13 |
| Net Current Asset | ₹8.53 | ₹5.03 | ₹8.83 | ₹8.96 |
| Non-Current Liabilities | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Equity Capital | ₹8.53 | ₹5.03 | ₹8.83 | ₹8.96 |
| Total Equity & Liabilities | ₹8.84 | ₹5.21 | ₹8.97 | ₹9.09 |
Genesis IBRC India Limited is an India-based biotechnology company. The Company is focused on developing and delivering microbial and antimicrobial products and services. The Company is involved in the manufacturing and marketing a range of specialties in various fields of aquaculture, agriculture, poultry and animal husbandry.
CCME GLOBAL LIMITED share price is ₹121.55 as on 02 Jul, 2026, 15:29 IST.
The Mutual Fund Shareholding in CCME GLOBAL LIMITED was 0.00% at the end of Apr 2026.
The 52-week high and low of CCME GLOBAL LIMITED share is ₹184.90 and ₹22.28 as of 02 Jul, 2026.
The market capitalisation of CCME GLOBAL LIMITED is ₹0.00 Crores as on 02 Jul, 2026.
The stock symbol of CCME GLOBAL LIMITED is 514336 on the BSE, and the ISIN is INE194N01016.
To buy CCME GLOBAL LIMITED shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
CCME GLOBAL LIMITED shares closed yesterday at ₹121.10 on BSE
No, shares of CCME GLOBAL LIMITED or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell CCME GLOBAL LIMITED shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.